Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 22, 2022
Reporting Period: Single event date (June 22, 2022)
Business Context: The Company is an emerging growth company focused on developing therapies for neurological diseases. This filing reports the issuance of a specific U.S. patent related to its XPro® technology platform.
Key Financial Metrics
This Form 8-K filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly informational regarding a corporate event.
Material Changes
Patent Issuance: On June 22, 2022, the Company received U.S. Patent No. 11,365,229 titled "METHODS OF TREATING NEUROLOGICAL DISEASES."
Technology Scope: The patent covers the use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, specifically the Company's XPro® variants. It addresses peripheral administration methods to cross the blood-brain barrier (BBB) for treating Central Nervous System (CNS) diseases.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) but does not include specific forward-looking guidance, financial outlook, or management discussion within the text of the 8-K itself.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text beyond the standard nature of patent-dependent biotechnology development.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed commercial implications of the patent.
- Confirm the specific claims and expiration date of U.S. Patent No. 11,365,229 via the USPTO database.
- Review the Company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K contains no financial data.
- Assess the competitive landscape for DN-TNF variants targeting CNS diseases.